Tia in the News

New regulatory framework brings gene and cell therapies under formal oversight while controversial pricing changes could reshape access to essential medicines

Integration of telomere length analysis and genetic sequencing into routine practice is changing diagnoses and treatment decisions for lung disease patients

Preclinical studies reveal engineered vascular organoids can integrate with damaged heart tissue and restore blood flow, offering a regenerative alternative to traditional bypass surgery.

A groundbreaking UK study demonstrates that early intervention with an existing drug can prevent the onset of debilitating autoimmune disease in high-risk patients, opening the door for AI-powered predictive screening.

A decade-long analysis of 15 million NHS contacts reveals that daily weather fluctuations—from temperature swings to rainfall—significantly influence mental health service demand, opening new frontiers for AI-powered healthcare forecasting.

New national registry standardizes pharmaceutical data across the world's most populous nation, creating infrastructure for AI-driven clinical tools and medication safety systems.

Xellar's AI-powered platform combines 3D tissue imaging and spatial omics to create comprehensive biological maps that could revolutionize drug discovery and precision medicine.

KAIST researchers reveal the molecular mechanism behind anti-VEGF therapy resistance, pointing toward AI-driven combination treatments that could finally stop cancer's vascular hijacking.

Australian researchers have developed a soft robotic heart that uses artificial intelligence to replicate both healthy and diseased cardiac conditions, offering a breakthrough alternative for medical device testing.

Startup Queue emerges from stealth with autonomous pharmacy technology that eliminates human handling of medications while addressing critical workforce shortages.

New regulations expanding coverage caps, telemedicine reimbursement, and chronic disease benefits position Vietnam as a testing ground for digital health equity solutions.

Experity's purchase of Exdion Healthcare brings automated coding and claims management to half of America's urgent care clinics, potentially eliminating administrative bottlenecks that have plagued the industry for decades.

Aarogya Setu 2.0 transforms from pandemic tracker to comprehensive health platform with predictive analytics and automated insurance processing

Major pharmaceutical company taps generative AI platform to slash development timelines and identify novel drug candidates across multiple therapeutic areas.

EchoIQ's exclusive access to up to one million echocardiogram scans represents one of the largest cardiovascular imaging datasets secured for AI development in the Asia-Pacific region.

FDA approval of Tryngolza for ultra-rare pancreatitis disorder and major partnership for hereditary angioedema treatment signal growing confidence in antisense oligonucleotide technology.

Afternoon cardiac surgeries show significantly less heart muscle damage than morning procedures, as researchers discover our internal biological clocks may influence how patients respond to operations.

Geographic disparities and insurance gaps leave millions of American women facing both life-threatening care deserts and thousands in out-of-pocket childbirth costs despite living in the world's wealthiest nation.

ATAI Life Sciences' addition to the Russell 2000 and Russell 3000 indexes signals growing mainstream investment confidence in novel mental health therapeutics and could accelerate funding across the sector.

Pooling mental health data across twelve isolated mountain communities reveals hidden behavioral health crises driven by seasonal work instability and geographic isolation.

By pairing peer counselors with therapy dogs, one Georgia health system is breaking the stigma around mental health in emergency medical services.

Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.

Analysis of 2.3 million veterans reveals the updated vaccine formulation may offer unexpected cardiovascular protection alongside infection prevention benefits.

Most hospital AI projects fail not because the technology is flawed, but because foundational data infrastructure wasn't built first.

This internal sensing system continuously monitors heart rate, breathing, and metabolic states—and disruptions may explain why patients feel anxious or unwell without obvious cause.

Cellular reprogramming uses Yamanaka factors to reset the epigenetic clock without erasing cell identity, with Life Biosciences now testing this aging reversal approach in human glaucoma patients for the first time.

The partnership aims to create a purpose-built foundation model for clinical conversations, moving beyond adapted general-purpose AI to address unique medical communication challenges.

FDA's new guidance on Bayesian statistical methods opens the door to adaptive clinical trials that could accelerate drug development while reducing costs and patient exposure to ineffective treatments.

Verily deploys wastewater surveillance technology across World Cup host cities to detect disease outbreaks up to a week before symptoms appear in populations.

FDA's new guidance on Bayesian statistical methods opens the door to adaptive clinical trials that could accelerate drug development while reducing costs and patient exposure to ineffective treatments.

Merck commits up to $510 million in milestone payments to Protillion Biosciences for AI-powered antibody discovery using on-chip screening technology.

FDA clears first medical maggot product using Australian sheep blowfly larvae, breaking the single-species monopoly in biological wound debridement therapy.

AI-powered monitoring systems promise to help seniors age safely at home, but raise critical questions about privacy, autonomy, and the ethics of constant surveillance.

Healthcare organizations face mounting pressure to adopt autonomous AI systems or risk competitive obsolescence in what industry observers describe as a technological survival test.